| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0009 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0009 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.094 | 0.001 |